• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vbi Vaccines Inc CS (NQ: VBIV )

    0.7451 -0.0049 (-0.65%)
    Streaming Delayed Price Updated: 1:29 PM EDT, Jul 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Vbi Vaccines Inc CS

    < Previous 1 2 3 4 Next >
    VBI Vaccines Announces Results of Annual General Meeting
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Reports First Quarter 2024 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Reports Full Year 2023 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Reports Third Quarter 2023 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Reports Second Quarter 2023 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Results of Annual General Meeting
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Poster Presentation at EASL 2023
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Reports First Quarter 2023 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Appoints Vaughn Himes to Board of Directors
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines Reports Full Year 2022 Financial Results
    From VBI Vaccines Inc.
    Via Business Wire
    VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
    From VBI Vaccines Inc.
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.